AnHeart Therapeutics
Chen Lu's work experience includes positions at various law firms and companies.
From August 2021 to the present, Chen Lu has been working as an Associate Counsel/Legal Manager at AnHeart Therapeutics.
Prior to that, from November 2018 to July 2021, Chen Lu worked as a Law Clerk at Yuan Zheng & Associates.
From December 2017 to October 2018, Chen Lu was an Intern & Associate at Zheng & Karg LLP.
Chen Lu also had an internship position at Liu, Zheng, Chen & Hoffman LLP from August 2017 to December 2017.
In terms of education, Chen Lu earned a Juris Doctor degree from Fordham Law School, where they studied from August 2015 to May 2017.
Before that, from June 2016 to July 2016, Chen Lu had an internship at Song Law Firm.
Another internship was completed at Jun Chen Law Offices from May 2015 to July 2015 while studying for an LL.M. degree at Fordham Law School from July 2013 to December 2014.
Prior to pursuing further education, Chen Lu worked as a Legal Counsel at Lashou.com from March 2011 to August 2012, where they provided in-house legal support during the IPO filing process and handled corporate reorganization.
From March 2009 to March 2011, Chen Lu worked as a Legal Counsel at Allyes, providing in-house legal support for M&A deals and reorganization efforts.
Overall, Chen Lu has gained extensive experience in various legal roles and has a strong academic background in law.
Chen Lu's education history begins in 2003 when they attended the East China University of Political Science and Law. They pursued a Bachelor of Laws (LL.B.) degree in the field of Law and completed their studies in 2007.
In 2013, Chen Lu continued their education at Fordham University School of Law, obtaining a Master of Laws (LL.M.) degree with a specialization in Banking, Corporate, and Finance Law. They successfully completed this program in 2014.
Seeking further expertise in the field of Law, Chen Lu pursued a Juris Doctor (J.D.) degree at Fordham University School of Law from 2015 to 2017.
Additionally, Chen Lu obtained several certifications to enhance their legal qualifications. They obtained the NY Bar certification from the New York State Bar Association in March 2020. In May 2018, they acquired the NJ Bar certification from the New Jersey State Bar Association. Chen Lu also holds the PRC BAR Qualification, which was obtained through the Chinese Ministry of Justice. However, the specific month and year of obtaining this qualification are not provided.
AnHeart Therapeutics
AnHeart Therapeutics (“AnHeart”) is a clinical-stage global biopharmaceutical company developing a broad pipeline of novel precision oncology therapeutics with high unmet medical needs. Its lead asset, taletrectinib, is a potential best-in-class next-generation ROS1 inhibitor currently in Phase 2 trials for ROS1 TKI-naïve and TKI-pretreated patients with ROS1 fusion-positive non-small cell lung cancer (NSCLC). Taletrectinib has received Breakthrough Therapy Designation (BTD) from both the US FDA and China NMPA for the treatment of patients with advanced or metastatic ROS1+ NSCLC, who are either ROS1 TKI treatment naïve or previously treated with crizotinib. The Company’s pipeline also includes AB-218, a mIDH1 inhibitor in Phase 2 trials with good brain penetration for multiple solid tumors with mIDH1 mutations and AB-329, an AXL inhibitor in Phase 1 studies to be used in combination with checkpoint inhibitor or chemotherapies in NSCLC or other solid tumors. The Company operates from offices in the US and China.